Sarepta Therapeutics will resume trading at 2:20 pm ET, with quotation set to resume at 2:15 pm ET, according to Nasdaq. Shares had been halted, pending news, ahead of the company announcing that the U.S. Food and Drug Administration accelerated approval of Elevidys, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy, or DMD, with a confirmed mutation in the DMD gene.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- 3 Best Stocks to Buy Now, 6/23/2023, According to Top Analysts
- Sarepta halted, pending news, ahead of FDA decision on SRP-9001
- Sarepta trading halted, news pending
- Before the Move: Watch Sarepta ahead of FDA decision on DMD gene therapy
- Regenxbio files second patent infringement suit against Sarepta